Skip to main content
Back
Watch Compare

ELITE PHARMACEUTICALS INC /NV/

Data quality: 100%
ELTP
OTC Manufacturing Chemicals
$0.38
▲ $0.01 (2.70%)
Mkt Cap: 409.26 M
Price
$0.38
Mkt Cap
409.26 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—

Quick Summary

Key Takeaways

Revenue grew 34.90% annually over 5 years — strong growth
Earnings declined -121.46% over the past year
ROE of 61.18% indicates high profitability
Net margin of 30.98% shows strong profitability
Generating 17.24 M in free cash flow
P/E of 9.43 — trading at a low valuation

Growth

Revenue Growth (5Y)
34.90%
Above sector avg (1.82%)
Revenue (1Y)48.42%
Earnings (1Y)-121.46%
FCF Growth (3Y)N/A

Quality

Return on Equity
61.18%
Above sector avg (-53.58%)
ROIC35.81%
Net Margin30.98%
Op. Margin35.74%

Safety

Debt / Equity
N/A
Current Ratio7.34
Interest Coverage440.71

Valuation

PE (TTM)
9.43
Above sector avg (-1.48)
P/B Ratio5.10
EV/EBITDA7.99
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1366 peers)
Metric Stock Sector Median
P/E 9.4 -1.5
P/B 5.1 1.6
ROE % 61.2 -53.6
Net Margin % 31.0 -41.5
Rev Growth 5Y % 34.9 1.8
D/E — 0.3

Analyst Price Target

No analyst coverage available

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2026 — 113.37 M —

Earnings Surprises

Last 3 quarters
Quarter Est. EPS Actual EPS Surprise
Q42010 N/A $0.02 —
Q32010 N/A $0.01 —
Q22010 N/A -$0.05 —

All Fundamental Metrics
Growth
Revenue Growth (1Y) 48.42% Revenue Growth (3Y) 56.86%
Earnings Growth (1Y) -121.46% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 34.90% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 140.12 M Net Income (TTM) 43.41 M
ROE 61.18% ROA 35.63%
Gross Margin 51.06% Operating Margin 35.74%
Net Margin 30.98% Free Cash Flow (TTM) 17.24 M
ROIC 35.81% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 7.34
Interest Coverage 440.71 Asset Turnover 1.15
Working Capital 83.60 M Tangible Book Value 74.68 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 9.43 Forward P/E N/A
P/B Ratio 5.10 P/S Ratio 2.92
PEG Ratio N/A Forward PEG N/A
EV/EBITDA 7.99 Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield 4.21%
Market Cap 409.26 M Enterprise Value 409.26 M
Per Share
EPS (Diluted TTM) 0.04 Revenue / Share 0.13
FCF / Share 0.02 OCF / Share 0.02
EPS CAGR (1Y) -100.00% EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0.91% FCF Conversion 39.71%
SBC-Adj. FCF N/A Growth Momentum 13.52

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 84.04 M 56.63 M 34.16 M 32.26 M 25.38 M
Net Income -4.31 M 20.11 M 3.56 M 8.90 M 5.09 M
EPS (Diluted) 0.00 0.02 0.00 0.01 0.01
Gross Profit 40.09 M 26.36 M 16.59 M 14.80 M 11.87 M
Operating Income 19.60 M 10.79 M 3.68 M 5.07 M 2.10 M
EBITDA — — — — —
R&D Expenses 7.96 M 6.88 M 6.20 M 4.05 M 5.11 M
SG&A Expenses — — — — —
D&A 1.23 M 1.32 M 1.28 M 1.21 M 1.31 M
Interest Expense 128,234.0 588,622.0 1.11 M 191,816.0 259,598.0
Income Tax 4.26 M -19.65 M 424,028.0 -1.74 M —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 96.39 M 83.65 M 40.90 M 35.15 M 26.19 M
Total Liabilities 42.87 M 26.07 M 11.94 M 9.93 M 10.04 M
Shareholders' Equity 53.52 M 57.58 M 28.96 M 25.22 M 16.15 M
Total Debt — — — 1.36 M 1.47 M
Cash & Equivalents — 7.11 M 7.83 M 8.54 M 3.19 M
Current Assets 57.74 M 40.01 M 21.51 M 18.86 M 12.19 M
Current Liabilities 11.84 M 13.05 M 7.83 M 6.69 M 5.81 M